• OrangeCorvus@lemmy.world
    link
    fedilink
    English
    arrow-up
    23
    arrow-down
    4
    ·
    1 year ago

    Many years ago when Linus started to aggressively use clickbait titles and thumbnails, people were pissed at the beginning but he said something like, Youtube is forcing them to do it…yeah right. That’s kinda when I stopped watching them, I wasn’t a big fan before anyway.

    Besides the cooler block part, the most annoying one is that if you invest in companies, good for you but maybe at that point you should stop reviewing their products. You are not in a place where you can be objective anymore. They did that with Framework and I think he also has shares in AMD? He kept pumping them some time ago.

    I see the vast majority of comments on the video are “ehhh, I watch them for entertainment”. I don’t find them at all entertaining and I actively avoid their channels because 99% of the time, the information presented is very generic or has nothing to do with the product. Plus the atrocious thumbnails/titles…

    • _danny@lemmy.world
      link
      fedilink
      English
      arrow-up
      4
      arrow-down
      1
      ·
      1 year ago

      As far as I know, he has never had AMD stock.

      Personally I don’t see the framework investment as an overwhelming conflict of interest. It’s an amount of money that’s not excessive for him(using the figures from the GN video), so if it were to vanish it wouldn’t be life changing. It’s also unlikely to be a life changer for him if it were to 10x. It sounds like even if it were to 100x, it would only increase his net worth by 20%.

      It’s disclosed frequently and the investment is very public, so the viewer knows to be aware of that potential bias.

      The much larger issues are the countless errors in the video that can mislead millions of viewers with bad data and poor testing oversight… and of course how those errors are handled once they are pointed out. I’d wager 95% of viewers would never read a pinned comment. These errors and their treatment cast doubt on the multi million dollar investment into a lab dedicated to guiding purchasing decisions.